215 patents
Page 11 of 11
Utility
Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
1 Apr 20
Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
Filed: 26 Sep 19
Utility
Deuterated Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
18 Mar 20
Kurt Gordon PIKE, Bernard Christophe BARLAAM
Filed: 14 Mar 18
Utility
Methods of Treating Heart Failure with Preserved Ejection Fraction Employing Dapagliflozin and Compositions Comprising the Same
11 Mar 20
Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.
Anna Maria LANGKILDE
Filed: 17 Jul 19
Utility
Therapeutic Dendrimers
4 Mar 20
Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
Filed: 4 Apr 19
Utility
Novel Salts of Ijak Inhibitors and Methods of Using the Same
26 Feb 20
Anna Matilda Angelica PETTERSEN, James MCCABE, Carl-Johan AURELL
Filed: 16 Jul 19
Utility
[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES for Use In the Treatment of Proliferative Diseases
19 Feb 20
Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
Filed: 31 Jul 19
Utility
ANTI-IFNAR1 Antibodies with Reduced FC Ligand Affinity
19 Feb 20
The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
Filed: 14 Jul 19
Utility
Amino-triazolopyridine Compounds and Their Use in Treating Cancer
12 Feb 20
Maurice Raymond Verschoyle FINLAY, Frederick Woolf GOLDBERG, Attilla Kuan Tsuei TING
Filed: 29 Jul 19
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
15 Jan 20
Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 18 Mar 19
Utility
Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 And/or IL-13 to Their Respective Receptors
8 Jan 20
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof.
Andreas Hohlbaum, Laurent Audoly, Beverly Koller
Filed: 15 Jul 19
Utility
2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE Compounds
25 Dec 19
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant).
Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna KADAMBAR, Chandrasekhara Reddy CHINTAKUNTLA, Andiappan MURUGAN, Claudio Edmundo CHUAQUI
Filed: 18 Jun 19
Utility
1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer
25 Dec 19
Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
Filed: 2 May 19
Utility
Maleate Salts of a Quinazoline Derivative Useful As an Antiangiogenic Agent
11 Dec 19
The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.
James MCCABE
Filed: 3 Jan 19
Utility
JAK1 Selective Inhibitors
4 Dec 19
Karl Magnus NILSSON, Annika Birgitta Margareta ASTRAND, Anna Ingrid Kristina BERGGREN, Johan R. JOHANSSON, Matti Juhani LEPISTO, Sameer Pralhad KAWATKAR, Qibin SU, Jason Grant KETTLE
Filed: 15 Jan 18
Utility
Chemical Compounds
30 Oct 19
Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
Filed: 9 May 19